25 Discussion Questions for Bad Blood by John Carreyrou (With Analysis)
Talk this through with a Chapterly AI tutor
Ask anything about this article. Your first 2 messages are free — no signup required.
Quick Answer: The strongest Bad Blood discussions resist treating Elizabeth Holmes as a singular villain and instead examine the system that produced and protected her — the celebrity board with no scientific expertise, the investors who skipped due diligence, the Silicon Valley norms that rewarded exaggeration. Frame the conversation around a single question: at each stage, who could have stopped Theranos, and why didn't they? That moves a group past the spectacle of the fraud and into the governance, incentive, and whistleblowing failures that actually let it continue for over a decade.
John Carreyrou's Bad Blood is one of the most gripping business books of the twenty-first century, and Bad Blood discussion questions force readers to confront uncomfortable truths about how fraud thrives in plain sight. The story of Theranos — the blood-testing startup that promised to revolutionize healthcare but delivered nothing but deception — is a case study in how charisma, ambition, and willful ignorance can combine to create catastrophic harm. Whether you are part of a business book club, an ethics course, or a leadership development program, these questions are designed to move beyond the spectacle and into the systemic failures that enabled Elizabeth Holmes's fraud.
Published in 2018, the book is based on Carreyrou's Pulitzer Prize-winning reporting for the Wall Street Journal. It details how Theranos raised nearly $1 billion, achieved a $9 billion valuation, and attracted some of the most powerful people in American business and politics to its board — all while its core technology never worked. Patients received inaccurate blood test results that led to real medical harm.
These 25 questions are organized by theme.
What Readers Most Commonly Get Wrong About Bad Blood
"Theranos failed because the technology did not work." This is the surface-level reading, and it misses the deeper story. Plenty of startups pursue ambitious technology that does not work — most pivot or shut down without harming anyone. What made Theranos catastrophic was not the technological failure but the governance failure. The board was stacked with political celebrities — Henry Kissinger, George Shultz, Jim Mattis — rather than scientists, engineers, or healthcare executives who might have asked basic technical questions. The absence of domain expertise at the governance level meant there was no mechanism to challenge Holmes's claims. The book is ultimately about how institutional structures fail, not about one company's R&D problems.
"Elizabeth Holmes was uniquely deceptive — a singular bad actor." Carreyrou's reporting actually reveals something more uncomfortable: Holmes operated within a Silicon Valley culture that systematically rewards exaggeration and punishes caution. The "fake it till you make it" ethos, the expectation that founders project unshakeable confidence, the investor preference for bold narratives over technical rigor — these are industry norms, not Holmes inventions. She was an extreme case of a normalized pattern. Reading her as a unique sociopath is reassuring because it implies the system is fine and only one person was broken. The book's evidence points in the opposite direction: the system produced her.
"The media and investors were duped by a master manipulator." This framing casts Holmes as an unusually skilled deceiver who fooled sophisticated people. But Carreyrou documents that many insiders raised alarms for years. Ian Gibbons, Theranos's chief scientist, was deeply troubled by the technology's failures. Multiple employees quit and tried to warn regulators or journalists. The story is less about people being unable to detect the fraud and more about people choosing not to see what was in front of them. Investors did not want to hear bad news about a company that confirmed their narrative about disruption. The failures were willful ignorance and motivated reasoning, not an inability to detect deception.
"Better regulation would have prevented this." This is the most common policy conclusion readers draw, and it oversimplifies the regulatory picture. CMS (Centers for Medicare and Medicaid Services) and the FDA actually did investigate Theranos and found serious problems — CMS revoked the company's lab certification and banned Holmes from operating a lab for two years. The regulatory mechanisms existed and eventually worked. The real failure was speed: regulators moved on bureaucratic timelines while Theranos moved on startup timelines, and patients received inaccurate results during the gap. The lesson is not that we need more regulation but that existing regulatory systems need the resources and mandate to move faster when public health is at stake.
Bad Blood Discussion Questions: Deception and Fraud
Carreyrou's investigation into Theranos raises questions that go far beyond one company's fraud. These opening questions force readers to confront the uncomfortable overlap between startup culture's celebration of bold vision and the kind of deception that endangered real patients. The discussion is most productive when participants resist the urge to treat Holmes as an anomaly and instead examine the systemic conditions that allowed Theranos to operate unchecked for over a decade.
1. Elizabeth Holmes modeled herself on Steve Jobs — the black turtleneck, the obsessive secrecy, the reality distortion field. Where is the line between visionary optimism and outright fraud? At what point did Holmes cross it, and could anyone have stopped her earlier?
2. Theranos's core technology never worked as promised, yet Holmes continued to raise money and sign partnerships. Is this fundamentally different from the "fake it till you make it" ethos common in Silicon Valley startups, or is it a natural extension of it?
3. The book reveals that Theranos ran most of its tests on competitors' machines rather than its own devices. How did the company maintain this deception for so long? What organizational structures enabled it?
4. Holmes reportedly believed she could will the technology into existence. Is it possible that she was not entirely conscious of the fraud — that she genuinely believed her own narrative? Does intent matter when patients are being harmed?
5. Carreyrou describes how Theranos used legal intimidation to silence former employees and journalists. How does the weaponization of NDAs and lawsuits enable corporate fraud? What reforms could prevent this?
Corporate Governance Failures
6. Theranos's board of directors included Henry Kissinger, George Shultz, Jim Mattis, and other prominent figures — none of whom had healthcare or technology expertise. How did this board composition enable rather than prevent the fraud? This is one of the most important cautionary tales in business literature.
7. The book shows how investors failed to perform basic due diligence. Walgreens invested $140 million without ever validating Theranos's technology. What psychological and institutional factors explain this failure?
8. Theranos operated with extreme secrecy, compartmentalizing information so that no single employee understood the full picture. How does secrecy function as a tool of control, and what are the warning signs that secrecy has crossed from competitive protection to fraud concealment?
9. Several employees raised concerns internally but were ignored, threatened, or fired. What does this pattern reveal about how organizations suppress dissent? How can companies create genuinely safe channels for raising concerns?
10. Tyler Shultz, the grandson of board member George Shultz, became a key whistleblower despite enormous family and legal pressure. What drove him to persist? What does his experience reveal about the personal cost of doing the right thing?
Silicon Valley Culture
11. The book portrays a culture in Silicon Valley where founders are treated as visionaries beyond questioning. How does the cult of the founder contribute to fraud? Is this problem unique to tech, or does it exist in other industries?
12. Holmes was celebrated as the youngest self-made female billionaire. How did media coverage and the desire for a compelling narrative contribute to the lack of scrutiny? What role did gender play in both the hype and the eventual backlash?
13. Theranos raised money from venture capitalists who prided themselves on being sophisticated investors. Carreyrou shows that many invested based on Holmes's charisma and the board's prestige rather than technology validation. What does this say about how venture capital actually works?
14. The book describes how Theranos used the language of "disruption" and "changing the world" to deflect criticism. When someone questions the company, they are framed as opponents of progress. How do you distinguish genuine innovation from innovation theater? Practicing how to read critically trains the same skepticism that the investors and board so conspicuously lacked.
15. After Theranos collapsed, many commentators said the warning signs were obvious in retrospect. Were they? What specific signals should have raised alarms earlier, and why were they missed? Working through how to analyze a book helps you separate Carreyrou's evidence from the hindsight narrative that has grown up around the case.
Whistleblowing and Journalism
16. Carreyrou's reporting was the catalyst for Theranos's downfall. What does this case reveal about the role of investigative journalism in holding powerful organizations accountable? Could the fraud have been uncovered without a journalist?
17. The whistleblowers in this story — Tyler Shultz, Erika Cheung, and others — faced legal threats, personal attacks, and enormous stress. What protections exist for whistleblowers, and are they adequate? Following these stories builds critical thinking skills for professional development.
18. Several sources initially refused to talk to Carreyrou because they had signed NDAs or feared legal retaliation. How should journalists navigate the tension between protecting sources and getting the story?
19. The book shows how Holmes used her media access and powerful connections to discredit Carreyrou's reporting before it was published. How should the public evaluate competing claims when a powerful organization pushes back against investigative reporting?
20. After the Wall Street Journal published its first story, Theranos held a press conference and Holmes appeared on multiple TV shows to deny the allegations. Many people believed her. What made her denials effective, and what eventually broke through?
Accountability and Lessons
21. Elizabeth Holmes was convicted of fraud in 2022. Is criminal prosecution the right mechanism for holding fraudulent founders accountable, or does the legal system move too slowly to be an effective deterrent?
22. Many people associated with Theranos — board members, investors, and partner executives — faced no meaningful consequences. Should there be accountability for those who enabled the fraud through negligence, even if they did not participate in it directly?
23. What structural reforms — in corporate governance, venture capital, regulatory oversight, or journalism — would make another Theranos less likely?
24. The book reveals that Theranos's flawed blood tests led to patients receiving inaccurate medical results, potentially affecting treatment decisions. How should we weigh the human cost of this fraud against the financial losses?
25. What is the most important lesson you take from Bad Blood? How does it change the way you evaluate claims of innovation, leadership, and disruption? Use active recall to keep these lessons sharp when evaluating future claims.
How to Get More From Your Reading
The best discussions start with strong preparation. If you want to remember the details when discussion time comes:
- Take notes by chapter using a method from our book notes guide
- Use active recall — close the book and try to explain each chapter's key events and ideas from memory. Here's why that works.
- Review your highlights before the discussion using spaced repetition
Related Discussion Guides
- Billion Dollar Loser Discussion Questions — WeWork's cautionary tale of founder excess.
- Super Pumped Discussion Questions — Uber's culture of growth at all costs.
- The Everything Store Discussion Questions — Amazon's relentless ambition under Bezos.
- Black Box Thinking Discussion Questions — Matthew Syed on learning from failure.
Preparing for a discussion of Bad Blood? Chapterly helps you retain and review the key ideas before your next meeting. Try it free.
Frequently Asked Questions
What is Bad Blood by John Carreyrou about?
Bad Blood is the inside story of Theranos, the blood-testing startup founded by Elizabeth Holmes that reached a 9 billion dollar valuation while its core technology never actually worked. Drawing on his Pulitzer Prize-winning Wall Street Journal reporting, Carreyrou documents how Holmes raised nearly a billion dollars, assembled a board of political celebrities, and ran most patient tests on competitors' machines — all while patients received inaccurate results that caused real medical harm. The book is ultimately a case study in how fraud thrives when governance, due diligence, and dissent all fail at once.
Is Bad Blood a true story?
Yes. Bad Blood is nonfiction, built on Carreyrou's own investigative reporting and on interviews with former Theranos employees, whistleblowers, and others connected to the company. Elizabeth Holmes was later convicted of fraud in 2022. Carreyrou was the journalist whose reporting was the catalyst for the company's downfall, which gives the book unusual proximity to the events it describes.
Is Bad Blood good for a business ethics book club?
It is one of the best available. The book raises governance, due diligence, whistleblowing, and Silicon Valley culture questions that map directly onto ethics courses and leadership programs. Discussions are most productive when the group resists treating Holmes as a unique villain and instead examines the systemic conditions — board composition, investor incentives, "fake it till you make it" norms — that allowed the fraud to persist.
What is the main lesson of Bad Blood?
The deepest lesson is that the Theranos disaster was a governance failure, not merely a technology failure. A board stacked with political prestige but no scientific expertise, investors who skipped basic validation, and a culture that punished caution combined to remove every mechanism that might have challenged Holmes's claims. The book argues that the system produced and protected the fraud — making it a warning about institutional structures rather than a story about one deceptive person.
How does Chapterly help with reading Bad Blood?
Chapterly is a nonfiction reading superapp for serious learners, built around AI-driven active reading and spaced repetition. It challenges readers to synthesize ideas after every chapter and draws connections to their previous highlights — so you actually remember what you read. With a fast-moving investigation like Bad Blood, that means the timeline of who knew what and when stays clear, so you can argue the governance and whistleblowing questions with the facts in front of you.
Discuss with the AI Tutor
The 25 questions above are built for group discussion. The prompts below are for one-on-one work with Chapterly's AI tutor — take a position, then let the tutor argue back. (Note: these reference real people and events, so the prompts paraphrase rather than invent quotations.)
1. Carreyrou's argument that Theranos was a governance failure more than a technology failure.
Defend or challenge this thesis. Plenty of startups pursue technology that does not work and harm no one. Argue with the tutor about whether the celebrity board — assembled for prestige rather than scientific or healthcare expertise — was the single decisive failure, or whether the technology fraud would have continued regardless of who sat on the board.
2. The book's evidence that Theranos operated within Silicon Valley norms, not outside them.
Take a position on the claim that the "fake it till you make it" ethos and investor preference for bold narratives produced Holmes rather than being violated by her. Argue with the tutor about whether reading her as a singular bad actor is reassuring precisely because it leaves the system unexamined.
3. The question of whether Holmes was consciously lying or genuinely believed her own narrative.
Pressure-test whether intent matters when patients are being harmed. Carreyrou leaves room for the possibility that Holmes believed she could will the technology into existence. Defend a position on whether self-deception is morally distinct from deliberate fraud when the downstream harm — inaccurate medical results — is identical.
4. The role of Tyler Shultz and Erika Cheung as whistleblowers under enormous legal and family pressure.
Argue about what actually drove them to persist when quitting quietly would have been far safer. Use their experience to take a position on whether existing whistleblower protections are adequate, and have the tutor defend the view that the system worked because the truth eventually came out.
5. The common reader conclusion that better regulation would have prevented Theranos.
Challenge or defend this. Carreyrou documents that CMS and the FDA did investigate and eventually acted — CMS revoked the lab's certification. Argue with the tutor about whether the real failure was the absence of regulation or the speed mismatch between bureaucratic timelines and startup timelines, and what that implies for policy.
Test Your Recall
Use these to check whether you retained the structure of the Theranos story or just remember the black turtleneck.
1. Why does Carreyrou frame Theranos as a governance failure rather than a technology failure? Answer: Because many startups chase technology that does not work and quietly fail without harming anyone — what made Theranos catastrophic was the absence of any mechanism to challenge Holmes. The board was filled with political celebrities like Henry Kissinger, George Shultz, and Jim Mattis rather than scientists or healthcare executives, so no one with domain expertise was positioned to ask basic technical questions. The fraud persisted because the institutional structures that should have caught it were missing, not because the science was uniquely hard.
2. How did Theranos conceal that its own technology did not work? Answer: The company ran most of its blood tests on modified commercial machines made by competitors rather than on its own Edison devices, while publicly claiming its proprietary technology was performing the analysis. It also operated with extreme secrecy and compartmentalization, so that no single employee could see the full picture, and it used aggressive NDAs and legal threats to silence former employees and journalists. This combination of misdirection, secrecy, and intimidation sustained the deception for years.
3. What role did investors and due diligence play in the Theranos story? Answer: Carreyrou shows that sophisticated investors repeatedly failed to perform basic validation. Walgreens, for example, committed 140 million dollars without ever independently verifying the technology. Many invested on the strength of Holmes's charisma and the prestige of the board rather than technical evidence. The book argues this reflects how venture capital often actually works — funding compelling narratives and confident founders — and how motivated reasoning led investors not to look closely at a company that confirmed their beliefs about disruption.
4. Who were the key whistleblowers and what did they risk? Answer: Tyler Shultz, the grandson of board member George Shultz, and Erika Cheung were among the employees who raised alarms and ultimately helped expose the fraud. They faced legal threats, surveillance, personal attacks, and, in Tyler's case, severe family pressure given his grandfather's loyalty to Holmes. Their persistence, alongside Carreyrou's reporting, was essential to bringing the truth to light, and their experience illustrates the steep personal cost of doing the right thing against a well-resourced organization.
5. What does Bad Blood suggest about the relationship between Silicon Valley culture and the fraud? Answer: The book argues that Holmes operated within, not outside, a culture that rewards exaggeration and punishes caution. The "fake it till you make it" ethos, the expectation that founders project unshakeable confidence, and the investor appetite for world-changing narratives over technical rigor are industry norms rather than Holmes inventions. Carreyrou's uncomfortable implication is that the system produced an extreme version of a normalized pattern, which is why reading Holmes as a lone sociopath misses the book's central point.
Preparing for a Bad Blood discussion? Chapterly helps you reflect on each chapter before you walk in. Try it free.